Roy Ebisu, MD
Internal Medicine · Aiea, HINPI 1427060763
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,045 and has fallen 94.8% since, to $211 in 2025. Among internal medicine clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $29.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi-aventis U.S. LLC$2K
- Novo Nordisk$1K
- Lilly USA, LLC$943
- Boehringer Ingelheim$888
- Amarin Pharma, Inc.$609
- plus $3K from 19 others
What the payments were for
- Travel & lodging$40%
- Food & beverage$10,657100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $2,390 |
| Sanofi-aventis U.S. LLC | 56 | $1,508 |
| Novo Nordisk | 57 | $1,373 |
| Lilly USA, LLC | 32 | $943 |
| Boehringer Ingelheim | 13 | $888 |
| Amarin Pharma, Inc. | 20 | $609 |
| GSK | 34 | $473 |
| Pfizer | 11 | $469 |
| Amgen(2 entities) | 12 | $443 |
| AbbVie(2 entities) | 18 | $407 |
| Bayer | 11 | $371 |
| Merck | 3 | $152 |
| Novartis | 3 | $115 |
| Teva Pharmaceuticals USA, Inc. | 1 | $114 |
| Astellas Pharma US Inc | 1 | $88 |
| Kowa Pharmaceuticals America, Inc. | 4 | $73 |
| Johnson & Johnson(2 entities) | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Gilead | 1 | $27 |
| Radius Health, Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,673 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $77,296 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 43 | $48,598 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $48,340 |
| JardianceEmpagliflozin | 29 | $29,952 |
| EliquisApixaban | 33 | $28,083 |
| JanuviaSitagliptin Phosphate | 17 | $26,427 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $16,474 |
| TrulicityDulaglutide | 17 | $16,393 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $14,713 |
| Praluent PenAlirocumab | 11 | $12,471 |
| FarxigaDapagliflozin Propanediol | 22 | $12,326 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $9,438 |
| Atorvastatin Calcium | 357 | $8,061 |
| Repatha SureclickEvolocumab | 12 | $6,407 |
| Losartan Potassium | 368 | $6,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia, Janumet Xr | $152 | $89,48065 claims |
| Novo NordiskOzempic | $1,373 | $77,29663 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,508 | $48,59843 claims |
| Boehringer IngelheimJardiance | $888 | $29,95229 claims |
| PfizerEliquis | $469 | $28,08333 claims |
| AstraZenecaFarxiga, Symbicort | $2,390 | $21,76453 claims |
| GSKTrelegy Ellipta | $473 | $16,47415 claims |
| Lilly USA, LLCTrulicity | $943 | $16,39317 claims |
| AbbVieSynthroid | $407 | $92819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Aiea
- Alan OkiAiea$13K
- Joel KobayashiAiea$11K
- Francis ButoAiea$10K
- Stephen MiyasatoAiea$10K
- Mark NishiharaAiea$9K
- Malissa Iida-TakashimaAiea$9K
- Michael MiharaAiea$8K
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.